For example, the rationale for targeting the JAK/STAT3 signaling axis in colorectal and pancreatic cancers builds on its established oncogenic role in hematologic settings, while the immunomodulatory functions of STAT1-STAT2 could inspire combination approaches with immune checkpoint inhibitors in solid tumors (297, 298). This evidence concerns the gene STAT1 and familial pancreatic carcinoma.